- Title:
Dividend Timetable Amendment - Time:
18:14:12 - Date:
14 Sept 2020 - Category:
Corporate updates - ID:
9573Y
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Dividend Timetable Amendment
Further to the interim results announcement released this morning, the dividend timetable should be amended to refer to the following key dates:
| Ex-dividend date: |
5 November 2020 |
| Record date: |
6 November 2020 |
| Payment date: |
1 December 2020 |
| EKF Diagnostics Holdings plc |
||
| Christopher Mills, Non-executive Chairman |
Tel: +44 (0) 29 2071 0570 |
|
| Julian Baines, CEO |
|
|
| Richard Evans, FD & COO |
|
|
| |
|
|
| N+1 Singer |
Tel: 020 7496 3000 |
|
| Aubrey Powell / George Tzimas (Corporate Finance) |
|
|
| |
|
|
| Walbrook PR Limited |
Tel: +44 (0) 20 7933 8780 or [email protected] |
|
| Paul McManus / Lianne Cawthorne |
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
Dividend Timetable Amendment18:14:1214 Sept 2020Corporate updates9573Y